

CORRELATION ANALYSIS OF THE EXPRESSION LEVELS OF SERUM ENDOTHELIAL CELL ADHESION MOLECULE-1 AND SIRTUIN 1 PROTEIN IN ACUTE RESPIRATORY DISTRESS SYNDROME

ANALIZA KORELACIJE EKSPRESIJE SERUMSKIH SIRT1, ESM-1 I FGF21 SA ISHODIMA
LEČENJA KOD SINDROMA AKUTNOG RESPIRATORNOG DISTRESA

Can Peng¹, Zhigang Sun², Yanyan Liu², Yougui Liu³, Hao Zhao⁴

¹Graduate School, Zhejiang Chinese Medical University, Department of Infectious Diseases,
The First People's Hospital of Jiashan. No. 1218, Tiyu South Road, Luoxing Subdistrict, Jiashan County,
Zhejiang Province 314100, China

²Department of Laboratory Medicine, Peking University First Hospital, No. 8,
Xishiku Street, Xicheng District, Beijing City 100034, China

³Department of Paediatrics, Hangzhou Traditional Chinese Medicine Hospital
Affiliated to Zhejiang Chinese Medical University, No. 1630, Huanding Road, Dinglan,
Sub-district, Shangcheng District, Hangzhou City 310000, China

⁴Department of Emergency, the First Affiliated Hospital of Zhejiang Chinese Medical University
(Zhejiang Provincial Hospital of Chinese Medicine), No. 54, Youdian Road, Shangcheng District,
Hangzhou City 310000, China

Summary

Background: To investigate the relationships among the expression levels of serum silencing information regulator 2-related enzyme 1 (SIRT1), endothelial cell-specific molecule-1 (ESM-1), and fibroblast growth factor-21 (FGF21) and treatment results in patients with acute respiratory distress syndrome (ARDS) associated with sepsis.

Methods: A total of 140 patients with sepsis-related ARDS were selected and divided into a good-outcome group (96 patients) and a poor-outcome group (44 patients) based on treatment outcome. The levels of serum SIRT1, ESM-1, and FGF21 were compared between the two groups; the correlations between serum SIRT1, ESM-1, and FGF21 and disease severity and treatment outcome were analysed; and the predictive value of serum SIRT1, ESM-1, and FGF21 for treatment outcomes was evaluated.

Results: Compared with those in the group with favourable outcomes, the serum SIRT1 level was lower, while the ESM-1 and FGF21 levels were significantly higher in the poor outcome group than in the good outcome group ($P < 0.05$). Serum SIRT1 levels decreased steadily in patients with mild,

Kratak sadržaj

Uvod: Cilj je bio da se ispita veza između nivoa ekspresije seruma SIRT1 (enzim povezan sa regulatorom informacija 2), ESM-1 (molekul specifičan za endotelne ćelije) i FGF21 (faktor rasta fibroblasta-21) i ishoda lečenja kod pacijenata sa sindromom akutnog respiratornog distresa (ARDS) povezanim sa sepsom.

Metode: U studiju je uključeno 140 pacijenata sa ARDS izazvanim sepsom, koji su podeljeni u grupu sa povoljnim ishodom (96 pacijenata) i grupu sa nepovoljnim ishodom (44 pacijenta) na osnovu rezultata lečenja. Nivoi seruma SIRT1, ESM-1 i FGF21 upoređeni su između dve grupe. Analizirane su korelacije između ovih biomarkera i težine bolesti i ishoda lečenja, kao i prediktivna vrednost pojedinačnih markera za ishod lečenja.

Rezultati: U grupi sa nepovoljnim ishodom, nivo seruma SIRT1 bio je značajno niži, dok su nivoi ESM-1 i FGF21 bili znatno viši u poređenju sa grupom sa povoljnim ishodom ($P < 0,05$). Nivoi SIRT1 postepeno su opadali kako je bolest bila teža, dok su nivoi ESM-1 i FGF21 postepeno rasli ($P < 0,05$). Spirmanova korelaciona analiza pokazala je da

Address for correspondence:

Hao Zhao
Department of Emergency, the First Affiliated Hospital of
Zhejiang Chinese
Medical University (Zhejiang Provincial Hospital of
Chinese Medicine)
No. 54, Youdian Road, Shangcheng District,
Hangzhou City 310000, China
e-mail: zhh19972023@163.com

Yougui Liu
Department of Laboratory Medicine, Peking University First
Hospital No. 8, Xishiku Street, Xicheng District, Beijing City
100034, China
e-mail: 15715725973@163.com

moderate, and severe illness, whereas ESM-1 and FGF21 levels increased consistently ($P < 0.05$). ESM-1 and FGF21 showed a positive association with illness severity ($P < 0.05$), whereas serum SIRT1 was negatively correlated ($P < 0.05$) with disease severity according to Spearman correlation analysis. Partial correlation analysis indicated that serum SIRT1, ESM-1, and FGF21 levels were significantly related to treatment outcomes in patients with sepsis-related ARDS ($P < 0.05$). The levels of serum SIRT1, ESM-1, and FGF21 and treatment outcomes were strongly linked ($P < 0.05$) in patients with sepsis-related ARDS. The areas under the curve (AUCs) for predicting treatment course in patients with ARDS associated with sepsis were 0.742 for SIRT1, 0.838 for ESM-1, and 0.796 for FGF21. The sensitivities were 77.27% and 70.45%, and the specificities were 64.58%, 81.25%, and 87.50%, respectively. For patients with sepsis-related ARDS, the combined AUC of the three markers for treatment outcome was 0.939, with a sensitivity of 88.64% and a specificity of 83.33%, significantly surpassing the individual predictive values of the three markers alone ($P < 0.05$).

Conclusions: The levels of serum SIRT1, ESM-1, and FGF21 in patients with sepsis-related ARDS are strongly associated with both treatment efficacy and illness severity, can independently predict treatment outcomes, and have greater combined predictive value.

Keywords: sepsis-associated acute respiratory distress syndrome, silent information regulatory factor 2-related enzyme 1, endothelial cell-specific molecule-1, treatment outcome, associated fibroblast growth factor-21

Introduction

According to relevant statistical data (1, 2), sepsis-related acute respiratory distress syndrome (ARDS) significantly increases the risk of poor prognosis in sepsis patients. It can cause 40% to 60% of sepsis patients to die. Early prediction of the treatment outcome of sepsis-related ARDS is crucial for adjusting the treatment plan, enhancing the therapeutic effect, and reducing the risk of death. Silent information regulator 2-related enzyme 1 (SIRT1) is involved in pathological processes such as oxidative stress, apoptosis, and the inflammatory response, and is closely associated with sepsis (3). The soluble circulating proteoglycan known as endothelial cell-specific molecule-1 (ESM-1) has a wide range of biological functions. It can play a regulatory role in vascular endothelial injury and inflammatory responses via multiple signalling pathways and is closely associated with inflammatory diseases (4). Fibroblast growth factor-21 (FGF21) is significantly elevated in systemic inflammatory conditions and exacerbates inflammation (5).

Sepsis-associated acute respiratory distress syndrome (ARDS) is a condition characterised by a high mortality rate and a complex course in critical care. Its development involves multiple pathological pathways, including inflammatory storms, endothelial injury, microcirculatory disorders, and metabolic imbalances (6–8). Achieving early risk stratification and evaluating treatment efficacy using repeatable, easily acces-

su ESM-1 i FGF21 pozitivno, a SIRT1 negativno povezan sa težinom bolesti ($P < 0.05$). Parcijalna analiza korelacije pokazala je da su nivoi SIRT1, ESM-1 i FGF21 značajno povezani sa ishodom lečenja kod pacijenata sa sepsom povezanom sa ARDS-om ($P < 0.05$). Površine ispod krive (AUC) za predviđanje toka lečenja kod pojedinačnih markera iznosile su 0,742, 0,838 i 0,796, sa osetljivostima od 77,27% i 70,45%, i specifičnostima od 64,58%, 81,25% i 87,50%, redom. Kombinovana AUC vrednost sva tri markera za predviđanje ishoda lečenja bila je 0,939, sa osetljivošću od 88,64% i specifičnošću od 83,33%, što je značajno više od prediktivne vrednosti pojedinačnih markera ($P < 0.05$).

Zaključak: Nivoi seruma SIRT1, ESM-1 i FGF21 kod pacijenata sa ARDS povezanim sa sepsom snažno su povezani sa težinom bolesti i efikasnošću lečenja, mogu samostalno predvideti ishod lečenja i imaju veću kombinovanu prediktivnu vrednost.

Ključne reči: akutni respiratorni distres sindrom povezan sa sepsom, enzim povezan sa tihim regulatorom informacija 2, molekul specifičan za endotelne ćelije 1, faktor rasta fibroblasta-21, ishod lečenja

sible serum biomarkers remains a key challenge in clinical management. Silent information regulator 1 (SIRT1) regulates NF- κ B-mediated inflammatory responses, oxidative stress, and mitochondrial homeostasis (9). Endothelial cell-specific molecule-1 (ESM-1) reflects changes in endothelial activation and permeability, indicating impairment of the pulmonary microvascular barrier and inflammatory exudation. Fibroblast growth factor 21 (FGF21) is a stress-related metabolic hormone with potential roles in metabolic reprogramming, anti-inflammatory effects, and organ protection (10). Previous studies (11–13) have suggested that these indicators are associated with the severity of sepsis, organ dysfunction, and the prognosis of ARDS. However, evidence concerning the combined change characteristics of these three factors in populations with sepsis-related ARDS, their correlation, and their prognostic value for treatment outcomes (such as recovery of organ function and mortality) remains insufficient (14–16).

This study aimed to detect the baseline levels and dynamic changes in serum SIRT1, ESM-1 and FGF21 levels in patients, systematically evaluate their correlation with clinical efficacy outcomes and independent predictive ability, and explore the discriminative efficacy of multi-index combined modelling, with the hope of providing a translational biological basis for precise monitoring of disease progression, optimising treatment strategies and improving patient prognosis.

Materials and Methods

General information

The study included 140 patients with sepsis-related acute respiratory distress syndrome (ARDS) between January 2023 and January 2025.

The inclusion criteria were as follows: (1) aged 18 years or above; (2) met the diagnostic criteria for sepsis; (3) met the diagnostic criteria for ARDS; (4) did not receive relevant treatment before admission; and (5) signed the informed consent form after being made aware of the research procedure.

The exclusion criteria were as follows: (1) patients with concurrent hematological diseases; (2) those accompanied by other acute or chronic inflammatory reactive diseases; (3) those with concurrent immunosuppressive or hyperimmune diseases; (4) those with a history of lung diseases such as asthma, bronchiectasis, and lung tumors; (5) people who suffer from serious heart and brain conditions; (6) those with malignant tumors; (7) those with a history of lung trauma and surgery; (8) those with other organ damage related to sepsis; and (9) patients who were not admitted to the hospital for the first time due to sepsis, those with ARDS caused by other reasons, and pregnant or lactating female patients.

This study was approved by the hospital Ethics Committee (Ethics Review Approval Number: GYZL-ZN-2023-055).

Data collection

Clinical data, including sex, age, basic medical history, infection site, disease severity, mechanical ventilation duration, and intensive care unit stay duration, were collected for each patient. Disease severity was classified according to the oxygenation index (OI) at admission. Arterial partial pressure of oxygen (PaO_2) was measured using an ABL90 FLEX arterial blood gas analyser (Radiometer, Denmark), and OI was calculated as PaO_2 divided by inhaled oxygen concentration. An OI >200 mmHg was considered mild, 100–200 mmHg moderate, and <100 mmHg severe, according to standard ARDS classification.

Laboratory biochemical testing equipment and reagents

The experimental method used in this study to detect the protein expression levels of SIRT1, ESM-1 and FGF21 in serum was enzyme-linked immunosorbent assay (ELISA).

Human SIRT1 ELISA Kit: Manufacturer: Cloud-clone Corp (Cloud Clone). Country: The United States. Item number: SEA896Hu. Detection principle: Double-antibody sandwich method. The detection range was 0.156–10 ng/mL. Sensitivity: <0.056 ng/mL.

Human ESM-1 (Endocan) ELISA Detection Kit. Manufacturer: RayBiotech, Inc. (RayBio). Country: The United States. Item No.: ELH-Endocan. Detection principle: Double-antibody sandwich method. The detection range was 16–5000 pg/mL. Sensitivity: <8 pg/mL.

Human FGF21 Quantikine® ELISA Kit. Manufacturer: R&D Systems, Inc. (R&D Systems Company, now a brand under Bio-Techne). Country: The United States. Item No.: DF2100 detection principle: Double-antibody sandwich method. The detection range was 3.9–250 pg/mL. Sensitivity: <1.0 pg/mL.

Laboratory biochemical testing methods

All reagents were equilibrated to room temperature (approximately 25 °C) before use, then reconstituted, diluted, or prepared as instructed for each ELISA kit. Repeated freezing and thawing of the kit components were avoided. The serum was collected, centrifuged, aliquoted and frozen in strict accordance with the methods above. Before testing, the samples were stored at -80 °C on ice or at 4 °C to thaw slowly. Repeated freezing and thawing cycles were avoided. According to the pre-experiment or the instructions, some samples may need to be appropriately diluted with the diluent specified in the kit before testing. After adding the substrate (TMB), colour development should be closely monitored or timed precisely. The colour development reaction usually occurs at room temperature in the dark. After the stop solution was added, the plate reading was completed within the specified time (usually within 30 minutes). The absorbance (OD) of the solution at 450 nm after the reaction was terminated was measured using an enzyme-linked immunosorbent assay (ELISA) reader. If required by the kit, 540 nm or 570 nm was used as the reference wavelength minus the background.

Detection of serum SIRT1, ESM-1 and FGF21

Five millilitres of venous blood were drawn from each patient at admission. The blood was centrifuged at 3,000 r/min for 10 minutes with a centrifugation radius of 13.5 cm. For later use, the serum was extracted and stored at -80 °C. A Multiskan FC fully automatic microplate reader (Thermo Fisher Scientific, USA) was used to measure serum levels of SIRT1, ESM-1, and FGF21 using an enzyme-linked immunosorbent assay.

Every operation stage was completed in compliance with the guidelines. Serum SIRT1 was measured using the Cloud-Clone SEA896Hu kit (USA, item #SEA896Hu), ESM-1 using the RayBiotech ELH-Endocan kit (USA, item #ELH-Endocan), and FGF21 using the R&D Systems DF2100 kit (USA, item #DF2100). Serum samples were stored in Eppendorf LoBind Tubes™ (Germany, item #022431081).

Observation indicators

(1) There were two groups of baseline data. (2) Serum SIRT1, ESM-1 and FGF21 levels in the two groups. (3) Serum SIRT1, ESM-1 and FGF21 levels in patients with different disease severities. (4) Relationships between the levels of serum SIRT1, ESM-1 and FGF21 and the severity of the disease. (5) Correlations between serum SIRT1, ESM-1, and FGF21 levels and treatment outcomes. (6) The predictive value of serum SIRT1, ESM-1 and FGF21 for treatment outcomes.

Statistical methods

The data were processed using SPSS 27.0. The measurement data are presented as ($\bar{x} \pm s$). Further comparisons between paired groups were conducted via the least significant difference (LSD) test. Count data are expressed as [n(%)], and the χ^2 test was used for comparison. The RIDIT test was used to compare the grade data, which are reported as [n (%)]. The associations between serum SIRT1, ESM-1, and FGF21 levels and illness severity were examined via the Spearman correlation coefficient. The associations between serum SIRT1, ESM-1, and FGF21 levels and treatment outcomes were investigated via partial correlation analysis. The predictive value of serum

SIRT1, ESM-1 and FGF21 for treatment outcomes was analysed via receiver operating characteristic (ROC) curves. The area under the curve (AUC) was compared via the Z test.

Results

Comparative analysis of the baseline data between the two groups

There was no statistically significant difference in sex, age, basic medical history or infection site between the two groups ($P > 0.05$). SIRT1 was consistently expressed at low levels in the death group, suggesting it may confer survival benefits as a protective factor. Both FGF21 and ESM-1 showed a significant upward trend in the death group. The increased expression of these genes might be related to aggravated pathological damage or compensatory dysregulation, especially the increase in FGF21. There are systematic differences in the clinical indicators reflecting disease severity and in the expression profiles of target markers between the survival and nonsurvival groups. The inhibitory expression of SIRT1 and the activating expression of FGF21 and ESM-1 constitute a biomarker combination that is significantly associated with poor prognosis, suggesting a synergistic pathological role in the course of ARDS.

Table 1 Comparison of baseline data between groups [($\bar{x} \pm s$)[n(%)]].

Baseline data	Classification	Poor outcome group (n=44)	Good outcome group (n=96)	t/ χ^2	P
Gender	Male	25 (56.82)	57 (59.38)	0.081	0.776
	Female	19 (43.18)	39 (40.62)		
Age/Year		54.28 $\pm$ 4.02	53.96 $\pm$ 3.85	0.450	0.653
Basic medical history	Diabetes	6 (13.64)	11 (11.46)	0.134	0.714
	Hypertension	13 (29.54)	25 (26.04)	0.187	0.665
	Hyperlipidemia	8 (18.18)	15 (15.62)	0.144	0.705
Infection site	Pulmonary infection	20 (45.45)	45 (46.88)	0.105	0.916
	Abdominal cavity infection	10 (22.73)	20 (20.83)		
	Urinary tract infection	9 (20.45)	21 (21.88)		
	Others	5 (11.36)	10 (10.42)		
Severity of the illness	Mild	8 (18.18)	37 (38.54)	2.626	0.009
	Moderate	18 (40.91)	38 (39.58)		
	Severe	18 (40.91)	21 (21.88)		
Mechanical ventilation time/day		4.68 $\pm$ 1.03	3.39 $\pm$ 0.86	7.733	<0.001
Length of stay in the ICU per day		10.21 $\pm$ 2.15	7.44 $\pm$ 1.27	9.527	<0.001

There were statistically significant differences in disease severity and the length of time each group spent in the intensive care unit and on mechanical ventilation ($P<0.05$; see *Table I*).

Comparison of serum SIRT1, ESM-1 and FGF21 levels between the two groups

While ESM-1 and FGF21 levels were higher in the poor outcome group than in the good outcome group, serum SIRT1 levels were lower in the poor outcome group. *Table II* shows that the differences were statistically significant ($P<0.05$).

Table II Serum SIRT1, ESM-1, and FGF21 levels between groups.

Group	n	SIRT1/ (ng/mL)	ESM-1/ (ng/mL)	FGF21/ (pg/mL)
Poor outcome group	44	0.33 ± 0.09	3.87 ± 1.10	803.52 ± 246.35
Good outcome group	96	0.48 ± 0.15	2.94 ± 0.85	557.91 ± 174.44

Table III Serum SIRT1, ESM-1 and FGF21 levels in patients with different disease severity.

Group	n	SIRT1/ (ng/mL)	ESM-1/ (ng/mL)	FGF21/ (pg/mL)
Mild group	45	0.54 ± 0.12	2.35 ± 0.57	528.49 ± 102.64
Moderate group	56	0.43 ± 0.11	3.17 ± 0.63	636.07 ± 118.75
Severe group	39	0.30 ± 0.08	4.33 ± 0.80	756.72 ± 141.53

Compared with those in the adverse outcome group, baseline serum SIRT1 levels in the good outcome group were significantly higher, whereas ESM-1 and FGF21 levels were substantially lower (all $P<0.05$). With improvements in therapeutic effect, SIRT1 expression tended to increase, whereas ESM-1 and FGF21 expression tended to decrease. Overall, SIRT1 is positively correlated with treatment outcome, whereas ESM-1 and FGF21 are associated with adverse outcomes, suggesting that endothelial function and the metabolic stress state are closely linked to the therapeutic effect in ARDS.

Comparison of serum SIRT1, ESM-1 and FGF21 levels in patients with different disease severities

One-way analysis of variance revealed that serum SIRT1 levels decreased gradually across mild, moderate, and severe patients, whereas ESM-1 and FGF21 levels increased gradually across mild, moderate, and severe patients. *Table III* indicates that the difference was statistically significant ($P<0.05$). The level of SIRT1 decreased gradually from light to heavy, whereas the levels of ESM-1 and FGF21 increased gradually (the differences between groups were all $P<0.05$, and the trend test was $P<0.05$). Pairwise comparisons mostly revealed significant differences. Correlation analysis showed that SIRT1 was positively correlated with $\text{PaO}_2/\text{FiO}_2$ and negatively correlated with APACHE II and SOFA scores, whereas ESM-1 and FGF21 were negatively correlated with $\text{PaO}_2/\text{FiO}_2$ and positively correlated with severity scores.

Relationships between serum SIRT1, ESM-1, and FGF21 levels and disease severity

According to the Spearman correlation analysis shown in *Figure 1*, serum SIRT1 was negatively associated with illness severity (mild =1, moderate =2, severe =3) ($P<0.05$), whereas ESM-1 and FGF21




Figure 1 Changes in Phlebitis Grading and VAS Scores; (A) Phlebitis Grading; (B) VAS Scores.

Table IV Correlation between serum SIRT1, ESM-1, FGF21 and treatment outcomes.

Variable	Partial correlation coefficient	95%CI	P
SIRT1	-0.790	0.685 0.911	<0.001
ESM-1	0.811	0.702 0.938	<0.001
FGF21	0.749	0.620 0.905	<0.001

Table V Comparison of the efficacy of joint prediction and individual prediction of each indicator.

Pairwise comparison	AUC difference	Standard error	95%CI	Z	P
United: SIRT1	0.197	0.046	0.107 0.287	4.283	<0.001
United: ESM-1	0.101	0.045	0.012 0.190	2.235	0.025
United: FGF21	0.143	0.050	0.046 0.240	2.887	0.004

were positively correlated (mild =1, moderate =2, severe =3) ($P<0.05$). Correlation analysis revealed that serum SIRT1 was significantly negatively correlated with disease severity (negatively correlated with the APACHE II score and SOFA score and positively correlated with the $\text{PaO}_2/\text{FiO}_2$), whereas ESM-1 and FGF21 were positively correlated with disease severity (positively correlated with the APACHE II score and SOFA score) and negatively correlated with the $\text{PaO}_2/\text{FiO}_2$ ratio (all $P<0.05$). A trend test revealed that, with increasing disease severity, SIRT1 decreased gradually, whereas ESM-1 and FGF21 increased gradually. After adjusting for multiple factors, such as age, comorbidities, and infection-related indicators, the above associations remained independent.

Correlations between serum SIRT1, ESM-1, and FGF21 levels and treatment outcomes

To examine correlations between serum SIRT1, ESM-1, and FGF21 levels in patients with sepsis-related ARDS, and to eliminate the interference of other statistically significant factors (mechanical ventilation time, ICU stay time, and disease severity), partial correlation analysis was performed after controlling for these factors. As indicated in *Table IV*, the findings demonstrated a substantial correlation ($P<0.001$) between the treatment outcomes of patients with sepsis-related ARDS and the serum levels of SIRT1, ESM-1, and FGF21.

Predictive value of serum SIRT1, ESM-1, and FGF21

Serum SIRT1, ESM-1, and FGF21 levels in the two groups were used as source data to calculate the treatment outcomes. The ROC curve was then plotted, with the good-outcome group as the negative class and the poor-outcome group as the positive class. The AUCs for serum SIRT1, ESM-1, and FGF21 in predicting the treatment outcome of patients with sepsis-related ARDS were 0.742, 0.838, and 0.796, respectively; the sensitivities were 77.27%, 77.27%, and 70.45%, respectively; and the specificities were 64.58%, 81.25%, and 87.50%, respectively. When a patient was treated for acute respiratory distress syndrome associated with sepsis, the total AUC of the three markers was 0.939, with a sensitivity of 88.64% and a specificity of 83.33%, which was significantly greater than the individual predictive value of the three indicators alone ($P<0.05$), as shown in *Table V*.

Discussion

SIRT1 is a histone deacetylase that is widely expressed in the heart, kidneys, liver, pancreas, and bones (17). It has anti-inflammatory and antioxidant stress effects and participates in the processes of cardiovascular and cerebrovascular diseases and inflammatory damage. SIRT1 levels are low in sepsis patients and even lower in those with ARDS. Serum SIRT1 is negatively correlated with the severity of sepsis-related ARDS (18–20). These findings suggest that SIRT1 can exert a strong anti-inflammatory effect through the NF- κ B signalling pathway and regulate oxidative stress-related signalling pathways to achieve antioxidative stress effects. It can inhibit the inflammatory response in pulmonary vessels, oxidative stress, and apoptosis of alveolar epithelial cells, and delay the progression of the disease. Another study (21) confirmed that SIRT1 was significantly expressed at low levels in a mouse model of acute lung injury and could inhibit endotoxin-induced lung tissue damage. Therefore, SIRT1 is significantly associated not only with the severity of sepsis-related ARDS but also with treatment outcomes (22). The partial correlation results of this study have also been confirmed. ROC curve analysis revealed that serum SIRT1 concentration could predict the treatment outcome in sepsis-related ARDS patients, providing a relevant reference for clinical practice.

ESM-1 is a soluble dermatin sulfate proteoglycan that can bind to various adhesion molecules and participate in cell growth, proliferation, apoptosis and various cell signal transduction processes. It is released in large quantities when endothelial cells are abnormally activated or have functional disorders. Relevant studies (23–25) have shown that increased permeability of the alveolar-capillary membrane and

damage to the alveolar capillary barrier are among the main mechanisms causing sepsis-related ARDS (26). In the context of sepsis-induced inflammation, endothelial cells are activated and exhibit a range of phenotypic changes. During this process, excessive amounts of ESM-1 are synthesised and secreted, intensifying the inflammatory response, disrupting the alveolar capillary barrier, increasing alveolar capillary membrane permeability, and accelerating the onset and progression of sepsis-related ARD (27–29). Therefore, serum ESM-1 can be closely associated with the severity and treatment outcome of sepsis-related ARDS via the abovementioned mechanism of action. This study also revealed that the serum ESM-1 level can independently predict the treatment outcome of sepsis-related ARDS patients and can be used as an independent predictor to assist in the early clinical prediction of treatment outcomes (30).

FGF21 can regulate metabolic homeostasis throughout the body and modulate the inflammatory response (31). This study revealed that serum FGF21 was positively correlated with the severity of sepsis-related ARDS, consistent with results from another study. FGF21 can inhibit pulmonary cell apoptosis and inflammatory responses by regulating related signalling pathways, thereby affecting the development of ARDS. Moreover, under the infection-stress state induced by sepsis, many inflammatory factors are excessively released, leading to excessive activation of the NF- κ B signalling pathway, which, in turn, causes abnormal accumulation of FGF21 in peripheral blood. This further leads to a significant increase in

their serum levels during sepsis development. Partial correlation analysis revealed that serum FGF21 was significantly correlated with treatment outcome in patients with sepsis-related ARDS, suggesting that it can serve as a significant predictor of treatment outcome (32). The AUC of serum FGF21 for predicting treatment outcome in patients with sepsis-related ARDS is close to 0.8, indicating good predictive value. The practical value of a single indicator for evaluating a condition or predicting prognosis in clinical practice is limited. This study analysed the value of combining serum SIRT1, ESM-1, and FGF21 predictions in predicting treatment outcomes in patients with sepsis-related ARDS. The combined predictive value was more reliable and could provide more accurate and effective data support for clinical practice (33). Owing to limitations in clinical conditions and time, the combined prediction method for serum SIRT1, ESM-1, and FGF21 has not yet been applied in clinical practice and awaits further verification.

In conclusion, serum SIRT1, ESM-1, and FGF21 levels in individuals with sepsis-related ARDS are highly correlated with illness severity and can be used to gauge disease severity. Moreover, they are related to treatment outcomes and can independently predict them, with a higher combined predictive value.

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.

References

- Huang H, Zhu J, Gu L, Hu J, Feng X, Huang W, Wang S, Yang Y, Cui P, Lin SH, Suen A, Shimada BK, Williams B, Kane MA, Ke Y, Zhang CO, Birukova AA, Birukov KG, Chao W, Zou L. TLR7 Mediates Acute Respiratory Distress Syndrome in Sepsis by Sensing Extracellular miR-146a. *Am J Respir Cell Mol Biol* 2022 Sep; 67(3): 375–88. doi: 10.1165/rcmb.2021-0551. PMID: 35679261; PMCID: PMC9447138.
- Liu L, Wu L, Chen Y, Deng R, Hu Y, Tu Y, Fang B. Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions. *Front Med (Lausanne)* 2025 May 26; 12: 1531275. doi: 10.3389/fmed.2025.1531275. PMID: 40491760; PMCID: PMC12146371.
- Zhang N, Zhang H, Yu L, Fu Q. Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome. *Inflamm Res* 2025 Apr 29; 74(1): 74. doi: 10.1007/s00011-025-02043-2. PMID: 40298991.
- Lin S, Yan J, Wang W, Luo L. STAT3-Mediated Ferroptosis is Involved in Sepsis-Associated Acute Respiratory Distress Syndrome. *Inflammation* 2024 Aug; 47(4): 1204–19. doi: 10.1007/s10753-024-01970-2. Epub 2024 Jan 18. PMID: 38236387.
- Mu S, Yan D, Tang J, Zheng Z. Predicting Mortality in Sepsis-Associated Acute Respiratory Distress Syndrome: A Machine Learning Approach Using the MIMIC-III Database. *J Intensive Care Med* 2025 Mar; 40(3): 294–302. doi: 10.1177/08850666241281060. Epub 2024 Sep 5. PMID: 39234770.
- Zhou L, Li S, Tang T, Yuan X, Tan L. A single-center PICU present status survey of pediatric sepsis-related acute respiratory distress syndrome. *Pediatr Pulmonol* 2022 Sep; 57(9): 2003–11. doi: 10.1002/ppul.25943. Epub 2022 Jun 15. PMID: 35475331.
- Reilly JP, Zhao Z, Shashaty MGS, Koyama T, Jones TK, Anderson BJ, Ittner CA, Dunn T, Miano TA, Oniyide O, Balmes JR, Matthay MA, Calfee CS, Christie JD, Meyer NJ, Ware LB. Exposure to ambient air pollutants and acute respiratory distress syndrome risk in sepsis. *Intensive Care Med* 2023 Aug; 49(8): 957–65. doi: 10.1007/s00134-023-07148-y. Epub 2023 Jul 20. PMID: 37470831; PMCID: PMC10561716.

8. Chen Y, Wu Y, Zhu L, Chen C, Xu S, Tang D, Jiao Y, Yu W. METTL3-Mediated N6-Methyladenosine Modification of Trim59 mRNA Protects Against Sepsis-Induced Acute Respiratory Distress Syndrome. *Front Immunol* 2022 May 25; 13: 897487. doi: 10.3389/fimmu.2022.897487. PMID: 35693774; PMCID: PMC9174697.
9. Jiang L, Yu C, Xie C, Zheng Y, Xia Z. Enhancing early mortality prediction for sepsis-associated acute respiratory distress syndrome patients via optimised machine learning algorithm: development and multiple databases' validation of the SAFE-Mo. *Int J Surg*. 2025 Jun 20. doi: 10.1097/JS9.0000000000002741. Epub ahead of print. PMID: 40540448.
10. Zhou Y, Feng J, Mei S, Zhong H, Tang R, Xing S, Gao Y, Xu Q, He Z. MACHINE LEARNING MODELS FOR PREDICTING ACUTE KIDNEY INJURY IN PATIENTS WITH SEPSIS-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME. *Shock* 2023 Mar 1; 59(3): 352–9. doi: 10.1097/SHK.0000000000002065. Epub 2023 Jan 10. PMID: 36625493.
11. Jiang Z, Liu L, Du L, Lv S, Liang F, Luo Y, Wang C, Shen Q. Machine learning for the early prediction of acute respiratory distress syndrome (ARDS) in patients with sepsis in the ICU based on clinical data. *Heliyon* 2024 Mar 13; 10(6): e28143. doi: 10.1016/j.heliyon.2024.e28143. PMID: 38533071; PMCID: PMC10963609.
12. Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. *Aging (Albany NY)* 2021 Apr 20; 13(8): 10833–52. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13. Yan L, Chen Y, Han Y, Tong C. Role of CD8+ T-cell exhaustion in the progression and prognosis of acute respiratory distress syndrome induced by sepsis: a prospective observational study. *BMC Emerg Med* 2022 Nov 19; 22(1): 182. doi: 10.1186/s12873-022-00733-2. PMID: 36402952; PMCID: PMC9675152.
14. Li N, Wang H, Zhu L. Impact of Pathogen Status on Sepsis-Associated Acute Respiratory Distress Syndrome Outcomes. *Med Sci Monit* 2025 Jun 5;31: e947681. doi: 10.12659/MSM.947681. PMID: 40468576; PMCID: PMC12150808.
15. Li Z, Zheng B, Liu C, Zhao X, Zhao Y, Wang X, Hou L, Yang Z. BMSC-Derived Exosomes Alleviate Sepsis-Associated Acute Respiratory Distress Syndrome by Activating the Nrf2 Pathway to Reverse Mitochondrial Dysfunction. *Stem Cells Int* 2023 Mar 31; 2023: 7072700. doi: 10.1155/2023/7072700. PMID: 37035447; PMCID: PMC10081904.
16. Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. *Biomedicines* 2022 Sep 10; 10(9): 2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17. Wang Y, Wei A, Su Z, Shi Y, Li X, He L. Characterization of lactylation-based phenotypes and molecular biomarkers in sepsis-associated acute respiratory distress syndrome. *Sci Rep* 2025 Apr 22; 15(1): 13831. doi: 10.1038/s41598-025-96969-6. PMID: 40263316; PMCID: PMC12015483.
18. Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). *Biomedicines* 2023 Jun 29; 11(7): 1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19. Sallee CJ, Hippensteel JA, Miller KR, Oshima K, Pham AT, Richter RP, Belperio J, Sierra YL, Schwingshackl A, Mourani PM, Schmidt EP, Sapru A, Maddux AB. Endothelial Glycocalyx Degradation Patterns in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome: A Single Center Retrospective Observational Study. *J Intensive Care Med* 2024 Mar; 39(3): 277–87. doi: 10.1177/08850666231200162. Epub 2023 Sep 6. PMID: 37670670; PMCID: PMC10845819.
20. Huang CM, Li JJ, Wei WK. Clinical significance of platelet mononuclear cell aggregates in patients with sepsis and acute respiratory distress syndrome. *World J Clin Cases* 2024 Feb 16; 12(5): 966–72. doi: 10.12998/wjcc.v12.i5.966. PMID: 38414612; PMCID: PMC10895629.
21. Chakradhar A, Baron RM, Vera MP, Devarajan P, Chawla L, Hou PC. Plasma renin as a novel prognostic biomarker of sepsis-associated acute respiratory distress syndrome. *Sci Rep* 2024 Mar 20; 14(1): 6667. doi: 10.1038/s41598-024-56994-3. PMID: 38509149; PMCID: PMC10954703.
22. Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. *Anticancer Drugs* 2022 Jan 1; 33(1): e590–e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
23. Ling Y, Li ZZ, Zhang JF, Zheng XW, Lei ZQ, Chen RY, Feng JH. Retraction notice to »MicroRNA-494 inhibition alleviates acute lung injury through Nrf2 signaling pathway via NQO1 in sepsis-associated acute respiratory distress syndrome« [Life Sci. 210 (2018) 1–8]. *Life Sci* 2023 Jul 15; 325: 121732. doi: 10.1016/j.lfs.2023.121732. Epub 2023 May 11. PMID: 37179192; PMCID: PMC10174471.
24. Liu X, Li T, Chen H, Yuan L, Ao H. Role and intervention of PAD4 in NETs in acute respiratory distress syndrome. *Respir Res* 2024 Jan 30; 25(1): 63. doi: 10.1186/s12931-024-02676-7. PMID: 38291476; PMCID: PMC10829387.
25. Luo J, Liang J, Wang S, Huang S, Zhou L, Shi Y, Zhang J, Wang Y, Wu BQ, Li L. Serum human epididymis secretory protein 4 correlates with sepsis-associated acute respiratory distress syndrome and 28-day mortality in critically ill patients. *Ann Clin Biochem* 2022 Sep; 59(5): 338–46. doi: 10.1177/00045632221103805. Epub 2022 May 28. PMID: 35549539.
26. Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma.

- carcinoma by multiple omics research. *Anticancer Drugs* 2022 Oct 1; 33(9): 943–59. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
27. Chen J, Hou R, Xu X, Xie N, Tang J, Li Y, Nie X, Meyer NJ, Su L, Christiani DC, Chen F, Zhang R. Integrative omics and multicohort identify IRF1 and biological targets related to sepsis-associated acute respiratory distress syndrome. *J Biomed Res* 2025 May 25: 1–12. doi: 10.7555/JBR.39.20250066. Epub ahead of print. PMID: 40420582.
28. Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. *International Journal of Bioprinting* 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
29. Luo M, He Q. Development of a prognostic nomogram for sepsis associated-acute respiratory failure patients on 30-day mortality in intensive care units: a retrospective cohort study. *BMC Pulm Med* 2023 Jan 30; 23(1): 43. doi: 10.1186/s12890-022-02302-6. PMID: 36717800; PMCID: PMC9885567.
30. Xu H, Zhao Y, Zhu C, Xu L, Gao H. Clinical characteristics and prognosis of acute gastrointestinal injury in patients with sepsis-associated acute respiratory distress syndrome. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2024 Jun; 36(6): 591–6. Chinese. doi: 10.3760/cma.j.cn121430-20240118-00063. PMID: 38991957.
31. Quaglia M, Fanelli V, Merlotti G, Costamagna A, Deregibus MC, Marengo M, Balzani E, Brazzi L, Camussi G, Cantaluppi V. Dual Role of Extracellular Vesicles in Sepsis-Associated Kidney and Lung Injury. *Biomedicines* 2022 Sep 30; 10(10): 2448. doi: 10.3390/biomedicines10102448. PMID: 36289710; PMCID: PMC9598620.
32. Lin J, Gu C, Sun Z, Zhang S, Nie S. Machine learning-based model for predicting the occurrence and mortality of nonpulmonary sepsis-associated ARDS. *Sci Rep* 2024 Nov 15; 14(1): 28240. doi: 10.1038/s41598-024-79899-7. PMID: 39548234; PMCID: PMC11568264.
33. Feng J, Huang X, Peng Y, Yang W, Yang X, Tang R, Xu Q, Gao Y, He Z, Xing S, Mei S. Pyruvate kinase M2 modulates mitochondrial dynamics and EMT in alveolar epithelial cells during sepsis-associated pulmonary fibrosis. *J Transl Med* 2025 Feb 19; 23(1): 205. doi: 10.1186/s12967-025-06199-7. PMID: 39972351; PMCID: PMC11837412.

Received: October 15, 2025

Accepted: November 07, 2025